A combination of a MEK/ERK-signaling inhibitor and three chromatin-remodeling molecules enhances generation of platelet-producing megakaryocytes in vitro, possibly through direct reprogramming.
BorstS, SimX, PonczM, et al. Induced pluripotent stem cell-derived megakaryocytes and platelets for disease modeling and future clinical applications. Arterioscler Thromb Vasc Biol, 2017; 37(11):2007–2013; doi: 10.1161/ATVBAHA.117.309197
3.
ChangY, ZhangX, HortonJR, et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol, 2009; 16(3):312–317; doi: 10.1038/nsmb.1560
4.
Hacein-Bey-AbinaS, EstienneM, BessolesS, et al. Erythropoietin is a major regulator of thrombopoiesis in thrombopoietin-dependent and -independent contexts. Exp Hematol, 2020; 88:15–27; doi: 10.1016/j.exphem.2020.07.006
5.
MatsunagaT, TanakaI, KobuneM, et al. Ex vivo large-scale generation of human platelets from cord blood CD34+ cells. Stem Cells, 2006; 24(12):2877–2887; doi: 10.1634/stemcells.2006-0309
6.
McCartyJM, SprugelKH, FoxNE, et al. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood, 1995; 86(10):3668–3675.
7.
PulecioJ, Alejo-ValleO, Capellera-GarciaS, et al. Direct conversion of fibroblasts to megakaryocyte progenitors. Cell Rep, 2016; 17(3):671–683; doi: 10.1016/j.celrep.2016.09.036
8.
ZarrabiM, AfzalE, AsghariMH, et al. Inhibition of MEK/ERK signalling pathway promotes erythroid differentiation and reduces HSCs engraftment in ex vivo expanded haematopoietic stem cells. J Cell Mol Med, 2018; 22(3):1464–1474; doi: 10.1111/jcmm.13379
